Jonathan Behr, Ph.D., joined SV Health Investors in 2019, bringing over 18 years of venture and venture creation experience. He co-leads the Dementia Discovery Fund (DDF) and serves as a Director or Observer on the Boards of several DDF portfolio companies, including Montara Therapeutics, Nitrase Therapeutics, QurAlis, Ribometrix, Sudo Therapeutics, Transposon Therapeutics and Violet Therapeutics, and had served on the Board of Caraway Therapeutics (acquired by MRK).
Previously, Jon was the first Managing Director of the T1D Fund, where he built the fund’s investment strategy, team, and portfolio, leading to notable successes such as Inversago Therapeutics (acquired by NVO), Pandion Therapeutics (PAND, acquired by MRK), Provention Bio (PRVB, acquired by SNY), and Semma Tx (acquired by VRTX). Before that, he served as Market Sector Leader and Executive in Residence at Partners Healthcare Innovation (now Mass General Brigham Innovation), leading neuroscience technology translation, with successes like Tilos Therapeutics (acquired by MRK). Jon has held senior venture creation roles at PureTech Ventures and Enlight Biosciences, where he co-founded and supported seven companies. He has served on or observed over 14 company boards throughout his career.
Outside of SV, Jon is an Independent Director of Parkinson's Research Ventures, a subsidiary of Parkinson’s UK.
Academic Credentials
Jon earned a Ph.D. in Biological Engineering from Massachusetts Institute of Technology as a Howard Hughes Medical Institute fellow, and received his B.S. in Bioengineering summa cum laude as phi-beta-kappa co-valedictorian from Rice University.
